ClinicalTrials.gg
CompletedNCT05712356BOLSTERUpdated Sep 28, 2026Results posted

A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

A Phase 2 interventional study of certepetide and Durvalumab in Cholangiocarcinoma, Gallbladder Cancer and Gallbladder Carcinoma, sponsored by Lisata Therapeutics, Inc.. Completed at 19 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Lisata Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Updated Sep 28, 2026Now CompletedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing cisplatin in Cholangiocarcinoma — 11 open to participants now, 12 under way, 3 of them phase 3. Cisplatin · Cholangiocarcinoma.

Enrollment
11th of 31
66 · median 33
Started
2023
with 2 others
Phase 2
19 of 31
6 open now
Registered
21st of 31
by date

Among the 31 studies testing cisplatin in Cholangiocarcinoma, this one is the 11th largest by enrollment, is one of 3 that started in 2023, is one of 19 in phase 2, and was the 21st registered.

Cholangiocarcinoma

825 studies on the registry are indexed under Cholangiocarcinoma; 288 are open to participants now.

Browse Cholangiocarcinoma studies →

Open to participants now

11 of the 31 studies testing cisplatin in Cholangiocarcinoma are open now, in 4 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About cisplatin

Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing cisplatin in Cholangiocarcinoma, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in patients with previously untreated cholangiocarcinoma or those that have progressed after first-line treatment for cholangiocarcinoma.

The main questions it aims to answer are:

  • is the new drug plus standard treatment safe and tolerable
  • is the new drug plus standard treatment more effective than standard treatment
Read the detailed description

This is a Phase 2a, double-blind, placebo-controlled, multi-center, randomized study of LSTA1 when added to standard of care (SoC) versus SoC alone in patients with advanced solid tumors. The study will include patients with previously untreated cholangiocarcinoma or those that have progressed after first-line treatment for cholangiocarcinoma.

The study will consist of a screening period, a run-in period, a treatment period, an end-of-treatment follow-up visit, and a long-term follow up period.

Participants who provide informed consent will be screened for eligibility within 28 days prior to beginning the study treatment run-in period. Once eligibility is confirmed, participants will be randomized to one of the two treatment groups (SoC + placebo vs. SoC + LSTA1).

During the 3-day run-in period, participants will only receive the LSTA1 or placebo components of their randomized treatment regimen. After the 3-day run-in, Cycle 1 of treatment will commence. Tumor scans will be performed every 8 weeks (56 days ± 7 days) while on treatment.

03

Conditions studied

  • Cholangiocarcinoma
  • Gallbladder Cancer
  • Gallbladder Carcinoma
  • Intrahepatic Cholangiocarcinoma
  • Extrahepatic Cholangiocarcinoma
  • Bile Duct Cancer
  • Gall Bladder Cancer
  • Gall Bladder Carcinoma

Keywords

  • immunotherapy
  • chemo
  • chemotherapy
  • first line
  • second line
  • progression
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) Performance Status of 0 or 1
  • ≥ 3 months
  • At least one as assessed by 1.1
  • Adequate organ and marrow function
  • Adequate
  • Patients with either of the following:

    • confirmed or unresectable cholangiocarcinoma or gallbladder carcinoma (GBC), with no prior systemic chemotherapy or targeted therapy or loco-regional therapy (including but not limited to transarterial chemoembolization, transarterial embolization, transarterial chemotherapy or transarterial radioembolization). Patients with recurrent disease more than 6 months after completion of chemotherapy following curative resection are eligible.
    • Pathologically confirmed metastatic or unresectable cholangiocarcinoma or GBC with progression of disease after chemotherapy and immunotherapy.

Exclusion criteria

Exclusion Criteria:

  • Any condition or comorbidity that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results, including but not limited to:

    • Any major surgery or irradiation less than 4 weeks prior to baseline disease assessment
    • Active infection (viral, fungal, or bacterial) requiring systemic therapy
    • Known active virus, virus, or infection
    • Active tuberculosis as defined per local guidance
    • History of allogeneic tissue/solid organ transplant
    • Prior requiring active treatment within the previous 3 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast
    • Pregnant or breastfeeding
    • or symptomatic cardiovascular/cerebrovascular disease (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) within 6 months before randomization
  • History or clinical evidence of symptomatic central nervous system (CNS)
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    LSTA1 arm for Untreated Cholangiocarcinoma

    Drug: certepetide · Drug: Durvalumab · Drug: Cisplatin · Drug: Gemcitabine

  • Experimental
    LSTA1 arm for Second-Line Cholangiocarcinoma

    Drug: certepetide · Drug: FOLFOX regimen

  • Placebo comparator
    Placebo arm for Untreated Cholangiocarcinoma

    Drug: Durvalumab · Drug: Cisplatin · Drug: Gemcitabine · Drug: Placebo

  • Placebo comparator
    Placebo arm for Second-Line Cholangiocarcinoma

    Drug: FOLFOX regimen · Drug: Placebo

Interventions

  • LSTA1 3.2 mg/kg given as a slow IV push over 1 minute when standard treatment(s) are given

    Also known as: CEND-1, LSTA1

  • 1500 mg of durvalumab IV administered over 1 hour every 21 days for 8 cycles then every 28 days for additional cycles

    Also known as: Imfinzi

  • cisplatin 25 mg/m² IV administered over 30 minutes on day 1 and day 8 every 21 days for up to 8 cycles

  • gemcitabine 1000 mg/m² IV administered over 30 minutes on day 1 and day 8 every 21 days for up to 8 cycles

  • The following will be given every 14 days: * oxaliplatin 85 mg/m² and l-folinic acid 200 mg/m² or d,l-folinic acid 400 mg/m² concurrently, as a 2-hour IV infusion * fluorouracil (5-FU) 400 mg/m² will be given as an IV bolus over 5 minutes * fluorouracil (5-FU) 2400 mg/m² will be administered over 46 hours (via home-infusion pump)

    Also known as: Oxaliplatin, Folinic acid, Fluorouracil

  • DrugPlacebo

    Placebo given as a slow IV push over 1 minute when standard treatment(s) are given

06

What researchers measure

Primary outcomes

  1. Number of Subjects Experiencing Any Adverse Event

    The National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE) will be used to grade the intensity of adverse events throughout the study

    Time frame: From time of consent until 30 days after treatment discontinuation, up to 18 months

07

Results

Posted May 26, 2026

Participant flow

Subjects were enrolled from May 2023 to February 2025. All enrolled subjects were from sites in the United States.

Participant flow — Overall Study
MilestoneLSTA1 Arm for Untreated CholangiocarcinomaLSTA1 Arm for Second-Line CholangiocarcinomaPlacebo Arm for Untreated CholangiocarcinomaPlacebo Arm for Second-Line Cholangiocarcinoma
Started23112111
Completed23112111
Not completed0000

Outcome measures

PrimaryNumber of Subjects Experiencing Any Adverse Event

The National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE) will be used to grade the intensity of adverse events throughout the study

Time frame:
From time of consent until 30 days after treatment discontinuation, up to 18 months
Reported as:
Count of participants · Participants
Number of Subjects Experiencing Any Adverse Event
ParticipantsLSTA1 Arm for Untreated CholangiocarcinomaLSTA1 Arm for Second-Line CholangiocarcinomaPlacebo Arm for Untreated CholangiocarcinomaPlacebo Arm for Second-Line Cholangiocarcinoma
Number of Subjects Experiencing Any Adverse Event23112111

Adverse events

Collected over Adverse event data were collected from time of consent, up to 18 months, or until patient death. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LSTA1 Arm for Untreated Cholangiocarcinoma12/23 (52.2%)10/23 (43.5%)23/23 (100%)
LSTA1 Arm for Second-Line Cholangiocarcinoma4/11 (36.4%)3/11 (27.3%)11/11 (100%)
Placebo Arm for Untreated Cholangiocarcinoma10/21 (47.6%)12/21 (57.1%)20/21 (95.2%)
Placebo Arm for Second-Line Cholangiocarcinoma2/11 (18.2%)4/11 (36.4%)11/11 (100%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventLSTA1 Arm for Untreated CholangiocarcinomaLSTA1 Arm for Second-Line CholangiocarcinomaPlacebo Arm for Untreated CholangiocarcinomaPlacebo Arm for Second-Line Cholangiocarcinoma
SepsisInfections and infestations1/230/112/210/11
FatigueGeneral disorders0/230/112/210/11
ColitisGastrointestinal disorders0/231/110/210/11
Blood bilirubin increasedInvestigations1/230/110/211/11
Platelet count decreasedInvestigations1/231/111/211/11
NeutropeniaBlood and lymphatic system disorders0/230/110/211/11
Bile duct stenosisHepatobiliary disorders0/230/110/211/11
FractureInjury, poisoning and procedural complications0/230/110/211/11
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/231/110/210/11
DeathGeneral disorders0/230/110/211/11
Most frequent other events
Showing 10 of 229
Most frequent other events
EventLSTA1 Arm for Untreated CholangiocarcinomaLSTA1 Arm for Second-Line CholangiocarcinomaPlacebo Arm for Untreated CholangiocarcinomaPlacebo Arm for Second-Line Cholangiocarcinoma
FatigueGeneral disorders12/236/1114/214/11
Decreased appetiteMetabolism and nutrition disorders4/237/114/212/11
ConstipationGastrointestinal disorders11/233/1112/215/11
NauseaGastrointestinal disorders6/235/1111/214/11
Platelet count decreasedInvestigations7/235/116/213/11
AnaemiaBlood and lymphatic system disorders10/232/119/212/11
Neutrophil count decreasedInvestigations8/234/119/214/11
DiarrhoeaGastrointestinal disorders6/233/112/214/11
ParaesthesiaNervous system disorders4/234/111/213/11
White blood cell count decreasedInvestigations4/234/116/213/11

Baseline characteristics

Age, Continuous
Age, Continuous(years)LSTA1 Arm for Untreated CholangiocarcinomaLSTA1 Arm for Second-Line CholangiocarcinomaPlacebo Arm for Untreated CholangiocarcinomaPlacebo Arm for Second-Line CholangiocarcinomaTotal
Mean63.2 ± 9.7462.6 ± 9.9963.5 ± 9.6762.5 ± 8.6662.9 ± 9.52
Sex: Female, Male
Sex: Female, Male(Participants)LSTA1 Arm for Untreated CholangiocarcinomaLSTA1 Arm for Second-Line CholangiocarcinomaPlacebo Arm for Untreated CholangiocarcinomaPlacebo Arm for Second-Line CholangiocarcinomaTotal
Female1069732
Male13512434
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LSTA1 Arm for Untreated CholangiocarcinomaLSTA1 Arm for Second-Line CholangiocarcinomaPlacebo Arm for Untreated CholangiocarcinomaPlacebo Arm for Second-Line CholangiocarcinomaTotal
Hispanic or Latino12429
Not Hispanic or Latino19915952
Unknown or Not Reported30205
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LSTA1 Arm for Untreated CholangiocarcinomaLSTA1 Arm for Second-Line CholangiocarcinomaPlacebo Arm for Untreated CholangiocarcinomaPlacebo Arm for Second-Line CholangiocarcinomaTotal
American Indian or Alaska Native01001
Asian21104
Native Hawaiian or Other Pacific Islander00000
Black or African American20002
White198191056
More than one race01012
Unknown or Not Reported00101
Region of Enrollment
Region of Enrollment(participants)LSTA1 Arm for Untreated CholangiocarcinomaLSTA1 Arm for Second-Line CholangiocarcinomaPlacebo Arm for Untreated CholangiocarcinomaPlacebo Arm for Second-Line CholangiocarcinomaTotal
United States2311211166
08

Study locations

19 sites
  • Banner MD Anderson Cancer Center
    Gilbert, Arizona 85234, United States
  • Mayo Clinic Arizona
    Phoenix, Arizona 85054, United States
  • University of Arizona Cancer Center
    Tucson, Arizona 85719, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Alliance for Multispecialty Research
    Merriam, Kansas 66204, United States
  • University of Kansas Cancer Center
    Westwood, Kansas 66205, United States
  • University of Kentucky Medical Center
    Lexington, Kentucky 40536, United States
  • Norton Cancer Institute, Downtown
    Louisville, Kentucky 40202, United States
  • Norton Cancer Institute, Audubon
    Louisville, Kentucky 40217, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
  • Northwell Health - Zuckerberg Cancer Center
    Lake Success, New York 11042, United States
  • Stony Brook Cancer Center
    Stony Brook, New York 11794, United States
  • FirstHealth of the Carolinas, Inc.
    Pinehurst, North Carolina 28374, United States
  • Carl & Edyth Lindner Center for Research & Education at The Christ Hospital and The Christ Hospital Cancer Center
    Cincinnati, Ohio 45219, United States
  • Spartanburg Medical Center
    Spartanburg, South Carolina 29303, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Inova Schar Cancer Institute
    Fairfax, Virginia 22031, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Apr 2026, 34 months.

Results were first posted in May 2026, 1 month after primary completion.

Of 173 phase 2 interventional studies under Cholangiocarcinoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's 34 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2023
First posted
Feb 3, 2023
StartActual
May 13, 2023
Primary completionActual
Apr 5, 2026
CompletionActual
Apr 5, 2026
Results first posted
May 26, 2026
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Terminated→Completed Reason for stopping removed
changed Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Terminated→Completed
    Why stopped Reason for stopping removed
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05712356
Lead sponsor
Lisata Therapeutics, Inc.
Responsible party
Sponsor
First posted
Feb 3, 2023
Start date
May 13, 2023
Primary completion
Apr 5, 2026
Completion
Apr 5, 2026
Results posted
May 26, 2026
Last update
Sep 28, 2026

Study contacts

Kristen K Buck, MD
study chair · Lisata Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Certepetide · Cisplatin · Gemcitabine · Folfox protocol

Start the discussion